Steve Duffy, Author at MPR
Steve Duffy

Steve Duffy

Digital Content Editor
Steve Duffy is the Digital Editor for MPR, part of the Medical Communications Group of Haymarket Media. He holds a BA in Media and Communications from Dundalk Institute of Technology and an MA in Journalism from Griffith College Dublin (both Ireland).

All articles by Steve Duffy

MPR Weekly Dose Podcast Episode 51

This week we cover AstraZeneca and the swift decision to restart their COVID-19 vaccine candidate trial; Pfizer and BioNTech want to expand enrollment for their candidate vaccine trial; There’s the Janus kinase inhibitor that could help reduce recovery time; An investigative antiviral may ease strain on hospitalizations; Aortic aneurysm, dissection assessed with fluoroquinolones; And a retrospective study compared cardiac events with azithromycin and amoxicillin use.

MPR Weekly Dose Podcast Episode 50

We cover AstraZeneca’s decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we wrap up the latest news on drugs in the pipeline.

MPR Weekly Dose Podcast Episode 49

The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.

MPR Weekly Dose Podcast Episode 48

Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.

MPR Weekly Dose Podcast Episode 47

This week we have remdesivir news; A new opioid and spinal muscular atrophy treatments are approved; A sublingual epinephrine treatment; And the latest on Biogen’s investigational Alzheimer disease treatment. Also, we have a brief summary of the other drugs in the pipeline from the past week.

MPR Weekly Dose Podcast Episode 46

This week there’s more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.

MPR Weekly Dose Podcast Episode 45

It’s been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There’s results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting SARS-CVv-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.

MPR Weekly Dose Podcast Episode 44

This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there’s new treatment for narcolepsy.